未找到相关数据
Sacral Neuromodulation in the Treatment of Interstitial Cystitis/Painful Bladder Syndrome: Should It Be Off Label?
被引：1
作者：
Mai Ahmed Banakhar
Tariq Faisal Al-Shaiji
Magdy Hassouna
机构：
[1] Toronto Western Hospital, Toronto, ON
关键词：
FDA;
Interstitial cystitis;
Off label;
Painful bladder syndrome;
Percutaneous nerve evaluation;
Sacral nerve stimulation;
Sacral neuromodulation;
US Food and Drug Administration;
D O I：
10.1007/s11884-012-0122-2
中图分类号：
学科分类号：
摘要：
The US Food and Drug Administration approved sacral neuromodulation (SNM) in 1997 as a treatment option for patients with urge incontinence and in 1999 for urgency/frequency and nonobstructive urinary retention. SNM uses direct, continuous stimulation of the third sacral nerves through implantation of a pulse generator and electrode. Off-label use of neuromodulation has been used successfully in patients with interstitial cystitis/painful bladder syndrome. This review attempts to provide an update on SNM as an off-label management option for adults with interstitial cystitis based on the available clinical evidence concerning its efficacy. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：120 / 124
页数：4
相关论文